SSRIs show weak advantage over bupropion for anxious depression Carlat Reports

SSRIs show weak advantage over bupropion for anxious depression

The Carlat Psychiatry Report, Volume 6, Number 7&8, July 2008
https://www.thecarlatreport.com/newsletter-issue/tcprv6n7-8/

From The Carlat Psychiatry Report, July 2008, Bipolar Disorder

Issue Links: Learning Objectives | Editorial Information

Topics: Depressive Disorder

Mark Zimmerman, MD

Last year, we reviewed a meta-analysis implying that bupropion is as effective as SSRIs for the treatment of patients with mixed anxiety and depression (TCPR, Aug 2007). In a new paper, these same researchers have sliced and diced the data a bit differently in order to answer this topic more confidently.

You can't view details of this content, please login or buy subscription here

Mark Zimmerman, MD

Director of Outpatient Psychiatry, Rhode Island Hospital Associate Professor of Psychiatry and Human Behavior Brown University School of Medicine

Dr. Zimmerman has disclosed that over the past 12 months he has been on the speaker’s bureaus for GlaxoSmithKline (and has spoken about the use of Wellbutrin) and for Wyeth Pharmaceuticals (Effexor XR and Pristiq), and has received between $20,000 and $50,000 for these activities. He has also received research grant support from Sepracor for the study of Lunesta, and has received between $20,000 and $50,000 for this activity. Dr. Carlat has determined that these financial relationships have not commercially biased this presentation.